CERE
Cerevel Therapeutics Holdings Inc
1 day chart
About CERE
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. It is advancing diverse pipeline with numerous clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy. Its pipeline candidates include Emraclidine, Darigabat, Darigabat and CVL-871.
Buy US stocks in Australia with $0 brokerage and trade CERE today!
$4.69B
-
0.00%
0
$30.18
$29.22
$0.00
$46.16
$19.86
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.